This stock is in 건강관리: revenue rank 58 of 287, share 0.4%.
58 / 2870.4%revenue share
Hana Pharm
293480 · KOSPI₩8,520+1.19%
2026-09-04 closeHana Pharm last closed at ₩8,520 (+1.19%) on 2026-09-04. Listed on KOSPI; price, financials and dividends update daily after market close.
Loading chart…
Close
No active signal.
New high + volume — the real recordrecord · not a prediction
Last 30 sessions
303 picks
Next-day win rate
50.7%
Avg next-day
-0.11%
vs market
-0.49%p
Every new-high-plus-volume pick we actually published (Korea market) — not this stock alone.
Trade plan
Fill entry, stop, account size and risk percent to get a share count. The stop must sit below the entry.
A calculator · not advice or a guarantee
Financials & valuation at a glance
A
Overall: 건강관리 43/291 · top 15%
Factor composite · relative position in sector
PER 7.13 · PBR 0.49 — own-history percentile 100/100 · 100/100
Open self-history band
PER100/100
PBR100/100
Factual information · not investment advice
Past reported results · not investment advice
More — deeper indicators
Annual dividend
Split-adjusted annual DPS history and available grade axes
Paid 7 consecutive years · Raised 0 consecutive years · Yield 5.99% (based on 2025 payment of 510원) · 3-year growth +0.0%
Per-share amount adjusted for splits and capital reductions · Factual information, not investment advice.
Financial safety
Reference indicatorAs of 2024Safe zoneFinancial-metric reference signal
Altman Z'' zoneZ'' 7.75
Distress
Grey
Safe
- Altman Z''
- 7.75
- Beneish M-Score
- -2.56
- Sloan accrual
- -1.06%
No statistical flag
부실·조작 위험을 나타내는 사실 지표입니다. 투자 조언이 아니며, 검증 전이라 참고용입니다.
Factual information, not investment advice.
Earnings quality · Piotroski F-Score
7/9Strong
Piotroski measures year-over-year financial improvement, not absolute quality.
Financial improvement score7/9
Profitability
- Positive ROAPass
- Positive OCFPass
- Improving ΔROANot passed
- Accruals (OCF > net income)Pass
Leverage & liquidity
- Lower debtPass
- Higher current ratioPass
- No new sharesPass
Efficiency
- Higher gross marginPass
- Higher asset turnoverNot passed
Calculation note: F7(신주)은 equity/asset 유지로 근사
Already-stable companies may score lower when year-over-year improvement is limited.
Factual information, not investment advice.
Industry structure
KRAs of 2026-09-05건강관리
Who dominates this industry?
- 1삼성바이오로직스7.3%
- 2셀트리온5.7%
- 3녹십자홀딩스3.5%
- 4유한양행3.3%
- 5대웅3.1%
- 6하나제약0.4%
Concentration
DistributedCR3 16.6%HHI and CR3 are separate industrial-organization facts; they are not the polarization verdict.
Polarization
Winner-take-all deepeningConsistentPolarization measures industry gaps and structure, not valuation, forecast, or investment advice.
Margin lens
- IQR%p
- 31.61
- Direction
- 확대
- Level
- 넓음
- Years
- 7
Value lens
- P90/P10
- 13.9
- Median P/B
- 1.47
- Level
- 넓음
- n
- 263
Survivorship note: 현재 산업 멤버십을 과거 연도에 소급 적용 — 과거 진입·퇴출 기업 미반영(복원 불가)
Factual information, not investment advice.
Risk sensitivity — adverse assumptions
Metric changes under stated assumptions; not a forecast or investment advice.
Base metrics
- Operating margin
- 11.2%
- Interest coverage
- —
- Return on equity (ROE)
- 6.9%
Operating margin −5pp
TolerableInterest coverageBase — adverse case —
Return on equity (ROE)Base 6.9% adverse case 3.4%
Revenue −15%
TolerableInterest coverageBase — adverse case —
Return on equity (ROE)Base 6.9% adverse case 5.2%
Key suppliers · Annual report
Annual reportDART · 2026-03-20Suppliers disclosed by the company in its 2026-03-20 annual report.
Suppliers without disclosed amount
VialAmple
Who held it · filings
Filed recordA historical record from curated-guru 13F filings and DART 5%+ major-holding disclosures.
US 13F는 분기 공시이며 최대 45일 뒤 제출될 수 있습니다.
5%+ major-holding disclosures
- 조동훈57.71%2024-10-28 · 증감 +0.05%p
Connections
AI-extracted related companies · for reference
Competitors
셀트리온Price comovement r=0.27 (1 year)유한양행Price comovement r=0.25 (1 year)종근당Price comovement r=0.26 (1 year)대웅제약Price comovement r=0.27 (1 year)JW중외제약Price comovement r=0.38 (1 year)한미약품Price comovement r=0.26 (1 year)동아에스티Price comovement r=0.43 (1 year)녹십자Price comovement r=0.34 (1 year)대원제약Price comovement r=0.40 (1 year)일동제약Price comovement r=0.19 (1 year)
Recent filings
Hana Pharm's latest filings on Korea's DART. Open a headline for a reference summary and the original.
Source: DART (Korea electronic disclosure)
About Hana Pharm
- What technical signals does Hana Pharm (293480) have?
- Hana Pharm current technical signals: no active technical signal.
- Is Hana Pharm a cup-and-handle pattern?
- No. Hana Pharm has no valid cup-and-handle signal right now.
- What are Hana Pharm's financials and valuation?
- Hana Pharm's income statement, balance sheet and cash flow are free for the most recent 8 years; the full history is on Pro. PER/PBR, dividend yield and sector valuation bands are free.
Like these rules? Backtest them.
Run this signal on this ticker in the free backtest builder — same window, no install.
Backtest this rule ↗Quantus Signal · live data · not investment advice · Privacy Policy